Table 2.
Patient Cohort Summary by PD-L1(+) Circulating Cells Associated with Malignancy (CCAM) Incidence.
| Characteristic | No detected PD-L1(+) CCAMs | >0–1.1 PD-L1(+) CCAMs/mL | >1.1 PD-L1(+) CCAMs/mL | p-value |
|---|---|---|---|---|
| Lung Cancer Cohort | 86 | 12 | 14 | |
|
| ||||
| Age, median (IQR), years | 67 (60–74) | 68.5 (61.75–75.75) | 70 (59–76.5) | 0.851 |
|
| ||||
| Tumor AJCC Stage | ||||
| I | 42 | 7 | 2 | 0.0265 |
| II | 12 | 2 | 2 | |
| III | 22 | 0 | 4 | |
| IV | 10 | 3 | 6 | |
|
| ||||
| Tumor Histological Type | ||||
| Adenocarcinoma | 62 | 7 | 11 | 0.918 |
| Squamous Cell Carcinoma | 14 | 3 | 2 | |
| Other | 10 | 2 | 1 | |
|
| ||||
| Clinical Site | ||||
| Yale | 61 | 8 | 3 | 0.00743 |
| Billings | 19 | 2 | 8 | |
| UCSD | 6 | 2 | 3 | |
|
| ||||
| Unhealthy Controls | 16 | 4 | 0 | |
CCAM = Circulating Cells Associated with Malignancy
IQR = Interquartile range
AJCC = American Joint Committee on Cancer